BeyondSpring Inc. (BYSI) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS
BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings data on Monday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.10, reports.
BeyondSpring (BYSI) opened at 40.97 on Monday. BeyondSpring has a one year low of $16.55 and a one year high of $48.49. The company has a 50-day moving average of $40.60 and a 200 day moving average of $31.34. The firm’s market cap is $889.34 million.
Several equities analysts recently weighed in on BYSI shares. HC Wainwright set a $43.00 price target on shares of BeyondSpring and gave the stock a “buy” rating in a report on Wednesday, May 31st. Rodman & Renshaw increased their price target on shares of BeyondSpring from $43.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, July 14th. Finally, Zacks Investment Research downgraded shares of BeyondSpring from a “hold” rating to a “sell” rating in a report on Monday, July 3rd.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/21/beyondspring-inc-bysi-releases-quarterly-earnings-results-misses-estimates-by-0-10-eps.html.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Stock Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related stocks with our FREE daily email newsletter.